	US 11,723,934 B2
	Compositions and methods for the induction of CD8+ T-cells
Kenya Honda, Tokyo (JP); Takeshi Tanoue, Tokyo (JP); Yutaka Kawakami, Tokyo (JP); Koji Atarashi, Tokyo (JP); Satoru Morita, Tokyo (JP); and Ashwin Nicholas Skelly, Tokyo (JP)
Assigned to Keio University, Tokyo (JP)
Appl. No. 16/968,263
Filed by Keio University, Tokyo (JP)
PCT Filed Feb. 8, 2019, PCT No. PCT/JP2019/004703 § 371(c)(1), (2) Date Aug. 7, 2020, PCT Pub. No. WO2019/156234, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/795,506, filed on Jan. 22, 2019.
Claims priority of provisional application 62/756,029, filed on Nov. 5, 2018.
Claims priority of provisional application 62/737,318, filed on Sep. 27, 2018.
Claims priority of provisional application 62/673,436, filed on May 18, 2018.
Claims priority of provisional application 62/628,501, filed on Feb. 9, 2018.
Prior Publication US 2022/0133813 A1, May 5, 2022
Int. Cl. A61K 35/741 (2015.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 35/00 (2006.01)

CPC A61K 35/741 (2013.01) [A61K 39/3955 (2013.01); A61P 31/04 (2018.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2035/115 (2013.01)]

17 Claims

1. A composition comprising:

(i) a purified bacterial mixture comprising two or more bacterial strains of species selected from Fusobacterium ulcerans and Eubacterium limosum, or Bacteroides dorei and Bacteroides uniformis, wherein the bacterial strains are lyophilized; and

(ii) one or more metabolites selected from the group consisting of mevalonate, dimethylglycine, hypoxanthine, IMP (inosine monophosphate), 2-deoxy-glucose 6-phosphate, TMP (trimethylpentane), 6PG (6-phosphogluconic acid), Rib5P (ribose 5-phosphate), Ru5P (ribulose 5-phosphate), Xu5p (xylulose 5-phosphate), GDP (guanosine 5′-diphosphate), GlcNAc 6P (N-acetylglucosamine-6-phosphate), UMP (uridine monophosphate), GMP (guanosine monophosphate), and CDP (cytidine diphosphate).